NVS: Novartis AG - Summary | Jitta

Novartis AG

NYSE:NVS

Price
$102.33
Loss Chance
45.2%
6.50JITTA SCORE
79.51%Over Jitta Line
Jitta Ranking
92 / 1,158
1,076 / 5,058
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (42)
Recent Business Performance (59)
Financial Strength (76)
Return to Shareholders (82)
Competitive Advantage (71)
Jitta Signs
Revenue and EarningConsistent
Operating MarginConsistent
Debt LevelLow Long Term Debt
Share RepurchaseEvery Year
CapExVery Low
Interest Coverage RatioVery Good
SG&A to SalesDecreasing Every Year
Recent Business PerformanceEarning decline 55.43% in the last year
Key Stats
Jitta Score
Jitta Line
6.50
79.51%
1.97
169.24%
2.00
168.74%
Pharmaceuticals
2.62
91.57%
6.63
34.28%
4.26
83.16%
COMPANY DESCRIPTION
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.